News

Oxygen Biotherapeutics, a company engaged in the business of developing biotechnology products with a focus on oxygen delivery to tissue, has filed an application with the FDA to

Wyeth Pharmaceuticals, a division of Wyeth, has reported that FDA has granted priority review to the company’s biologic license application or BLA for Prevnar 13, a Pneumococcal 13-valent

Swedish biotech company Axelar has completed the single-day oral dosing part of its ongoing Phase I/II clinical trial on cancer patients with its new anticancer drug AXL1717, an

Amarin, an Ireland-based clinical-stage biopharmaceutical company, has reached an agreement with the FDA under a special protocol assessment for its planned Phase III registration clinical trial of AMR101

First quarter 2009 product revenues consisted of $1.3 million in Celution System sales in Europe and Asia and the recognition of $0.6 million from the installation of a

Revenues for the nine months ended March 31, 2009 were $29.3 million, a $1.3 million decrease against revenues of $30.6 million for the nine months ended March 31,

Biovail Corporation has reported that its subsidiary Biovail Laboratories International has entered into an agreement to acquire full US commercialization rights to Wellbutrin XL tablets from GlaxoSmithKline. Under

Instrumentation Laboratory, a developer and manufacturer of diagnostic medical equipment, has received the FDA’s 510(k) clearance for the ACL AcuStar hemostasis testing system. This clearance allows Instrumentation Laboratory

Potentia Pharmaceuticals, a biotechnology company, has successfully completed its Phase I ASaP clinical trial for POT-4, the company’s lead drug candidate for the treatment of age-related macular degeneration.